Vera Therapeutics' First-in-Class Kidney Disease Drug Lands Speedy FDA Approval
Vera Therapeutics' First-in-Class Kidney Disease Drug Lands Speedy FDA Approval (MedCity News.)
Vera Therapeutics
Vera Therapeutics is a late-stage clinical biopharmaceutical company developing treatments for serious immunological diseases. Its lead asset atacicept (a dual BAFF/APRIL inhibitor) received FDA approval in 2026 for IgA nephropathy (IgAN), establishing it as the first-in-class targeted therapy for this kidney disease.
Company Info
Sector:Biotechnology / Immunology
Headquarters:Brisbane, California, USA
Founded:2016
Website:www.veratx.com/
Recent News
Leadership Team
Careers & Job Openings